Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1AN | Q9NWT6 | 13/20 | 0.72 |
| ▸ | ODC1 | P11926 | 2/20 | 0.72 |
| ▸ | ACHE | P22303 | 2/20 | 0.68 |
| ▸ | BCHE | P06276 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16694587 | 1.00 | HIF1AN (0.72) | HIF1ANODC1ACHEBCHEPTPN1 | |
| SCHEMBL16865504 | 0.93 | HIF1AN (0.68) | HIF1ANODC1ACHEBCHEPTPN1 | |
| SCHEMBL16694436 | 0.91 | HSP90AA1 (0.61) | HIF1ANODC1ACHE | |
| SCHEMBL16694437 | 0.91 | HSP90AA1 (0.61) | HIF1ANODC1ACHE | |
| SCHEMBL31376273 | 0.89 | ACHE (0.73) | HIF1ANODC1ACHEBCHEPTPN1 | |
| SCHEMBL31376223 | 0.88 | HIF1AN (0.69) | HIF1ANODC1ACHEBCHEPTPN1 | |
| SCHEMBL31376176 | 0.87 | HIF1AN (0.87) | HIF1ANODC1ACHEBCHEPTPN1 | |
| SCHEMBL16694388 | 0.87 | HIF1AN (0.87) | HIF1ANODC1ACHEBCHEPTPN1 | |
| SCHEMBL16694389 | 0.87 | HIF1AN (0.87) | HIF1ANODC1ACHEBCHEPTPN1 | |
| SCHEMBL31376228 | 0.86 | HIF1AN (0.69) | HIF1ANODC1ACHEBCHEPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118311178-A | Method for simultaneously measuring 22 chemical components in nose-sensitive capsule by using UPLC-MS/MS | 山东省中医药研究院 | 2024-07-09 | — | — | CN | claimed |
| CN-115128186-A | Fingerprint spectrum construction method, component basic identification construction method and detection method of magnolia flower rhinitis preparation | 广州白云山中一药业有限公司 | 2022-09-30 | — | — | CN | claimed |
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | claimed |
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2015-07-02 | — | — | US | claimed |
| EP-2871187-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB Foundation (KR) | 2015-05-13 | — | — | EP | claimed |
| CN-118903074-A | Application of licarpa root chalcone in preparation of anti-liver cancer drugs and anti-liver cancer drugs | 重庆医科大学国际体外诊断研究院 | 2024-11-08 | — | — | CN | disclosed |
| CN-114246847-B | Application of chalcone compounds in treatment of coronavirus infection | 北京化工大学 | 2024-01-16 | — | — | CN | disclosed |
| CN-111443154-B | Research method of medicinal genetic relationship of glycyrrhiza | 贵州中医药大学 | 2023-03-07 | — | — | CN | disclosed |
| CN-115128186-A | Fingerprint spectrum construction method, component basic identification construction method and detection method of magnolia flower rhinitis preparation | 广州白云山中一药业有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-115128186-A | Fingerprint spectrum construction method, component basic identification construction method and detection method of magnolia flower rhinitis preparation | 广州白云山中一药业有限公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | disclosed |
| EP-2871187-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2017-09-20 | — | — | EP | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-9745280-B2 | Compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient | SNU R&DB FOUNDATION (KR) | 2017-08-29 | — | — | US | disclosed |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2016-11-24 | — | — | US | disclosed |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2016-11-24 | — | — | US | disclosed |
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2015-07-02 | — | — | US | disclosed |
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB FOUNDATION (KR) | 2015-07-02 | — | — | US | disclosed |
| EP-2871187-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SNU R&DB Foundation (KR) | 2015-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183797-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HIF1AN | HIF1AN 3/4885ODC1 3423/4885ACHE 4868/4885 |
| US-20160340331-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HSP90AB1, HSP90AA1, HSP90AB2P | HIF1AN 4/4885ODC1 3782/4885ACHE 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.